We find that a molecular sub-cluster of colon cancer cells with low CDX2 and VDR expression is specifically sensitive to chemotherapy, BRAF inhibitors and PI3K-mTOR inhibitors treatment. Here, CDX2 is linked to malignant colon neoplasm.